Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 175, Issue 7, 2007, Pages 712-719

  Parimon, Tanyalak ^a   Chien, Jason W ^a,b   Bryson, Chris L ^a,c   McDonell, Mary B ^c   Udris, Edmunds M ^c   Au, David H ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Adherence; Chronic obstructive pulmonary disease; Lung cancer; Pharmacoepidemiology

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE;

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEALTH CENTER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SELF REPORT; TREATMENT INDICATION;

ADMINISTRATION, INHALATION; AGED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; UNITED STATES;

EID: 34047193053     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200608-1125OC     Document Type: Article

References (78)

1. U.S Cancer Statistics Working Group. United States Cancer Statistics: 2002 Incidence and Mortality. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2005.
2. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909.
3. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
4. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-239.
5. Samet JM. Smoking kills: experimental proof from the Lung Health Study. Ann Intern Med 2005;142:299-301.
6. Bechtel JJ, Kelley WA, Coons TA, Klein MG, Slagel DD, Petty TL. Lung cancer detection in patients with airflow obstruction identified in a primary care outpatient practice. Chest 2005;127:1140-1145.
7. Petty TL. Screening for lung cancer. Ann Intern Med 2004;141:649-650.
8. Carbone DP. Lung cancer: early events, early interventions: conference summary for the 46th Annual Thomas L Petty Aspen Lung Conference. Chest 2004;125:167S-172S.
9. Petty TL. Sputum cytology for the detection of early lung cancer. Curr Opin Pulm Med 2003;9:309-312.
10. Petty TL. Cost-effectiveness of screening for lung cancer. JAMA 2003;289:2357; author reply, 2358-2359.
11. Petty TL. The early diagnosis of lung cancer. Dis Mon 2001;47:204-264.
12. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550-1559.
13. Petty TL. Screening strategies for early detection of lung cancer: the time is now. JAMA 2000;284:1977-1980.
14. Fontana RS, Sanderson DR, Taylor WF, Woolner LB, Miller WE, Muhm JR, Uhlenhopp MA. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic Study. Am Rev Respir Dis 1984;130:561-565.
15. Frost JK, Ball WC Jr, Levin ML, Tockman MS, Baker RR, Carter D, Eggleston JC, Erozan YS, Gupta PK, Khouri NF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins Study. Am Rev Respir Dis 1984;130:549-554.
16. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer: results of the Memorial Sloan-Kettering Study in New York. Chest 1984;86:44-53.
17. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the US Preventive Services Task Force. Ann Intern Med 2004;140:740-753.
18. Artinian V, Kvale PA. Update in screening of lung cancer. Respirology 2005;10:558-566.
19. Schabath MB, Hernandez LM, Wu X, Pillow PC, Spitz MR. Dietary phytoestrogens and lung cancer risk. JAMA 2005;294:1493-1504.
20. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005;294:1505-1510.
21. Dragnev KH, Stover D, Dmitrovsky E. Lung cancer prevention: the guidelines. Chest 2003;123:60S-71S.
22. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003;163:1475-1480.
23. Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto A, Ravenna F, Calia N, Petruzzelli S, Corbetta L, Cavallesco G, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004;59:679-681.
24. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005;60:570-575.
25. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. Ann Intern Med 1986;105:503-507.
26. Petty TL. Are COPD and lung cancer two manifestations of the same disease? Chest 2005;128:1895-1897.
27. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002;57:799-803.
28. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-1596.
29. Greenberg AK, Hu J, Basu S, Hay J, Reibman J, Yie T-a, Tchou-Wong KM, Rom WN, Lee TC. Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators. Am J Respir Cell Mol Biol 2002;27:320-328.
30. Yao R, Wang Y, Lemon WJ, Lubet RA, You M. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expression. Oncogene 2004;23:7746-7752.
31. Parimon T, Chien J, Bryson C, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with COPD [abstract]. Proc Am Thorac Soc. 2006;3:A119.
32. Fihn SD, McDonell MB, Diehr P, Anderson SM, Bradley KA, Au DH, Spertus JA, Burman M, Reiber GE, Kiefe CI, et al. Effects of sustained audit/feedback on self-reported health status of primary care patients. Am J Med 2004;116:241-248.
33. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care 1988;26:814-823.
34. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother 1998;32:220-232.
35. Brewster D, Muir C, Crichton J. Registration of lung cancer in Scotland: an assessment of data accuracy based on review of medical records. Cancer Causes Control 1995;6:303-310.
36. Fan VS, Au DH, Heagerty P, Deyo RA, McDonell MB, Fihn SD. Validation of case-mix measures derived from self-reports of diagnosis and health. J Clin Epidemiol 2002;53:371-380.
37. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Arch Intern Med 1998;158:1789-1795.
38. Phibbs CS, Luft HS. Correlation of travel time on roads versus straight line distance. Med Care Res Rev 1995;52:532-542.
39. Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763.
40. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report. Updated 2003.Available from: http://www.goldcopd.com.
41. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-1823.
42. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-1953.
43. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-1091.
44. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
45. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-843.
46. Cazzola M, Dahl R. Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. Chest 2004;126:220-237.
47. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-997.
48. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56:515-548.
49. Turato G, Zuin R, Miniati M, Baraldo S, Rea F, Beghe B, Monti S, Formichi B, Boschetto P, Harari S, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002;166:105-110.
50. +T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-826.
51. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
52. Lapperre TS, Postma DS, Gosman MM, Snoeck-Stroband JB, ten Hacken NH, Hiemstra PS, Timens W, Sterk PJ, Mauad T. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax 2006;61:115-121.
53. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005;26:835-845.
54. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166:1218-1224.
55. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
56. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
57. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-217.
58. Gaydos CA. Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J Infect Dis 2000;181:S473-S478.
59. Littman AJ, White E, Jackson LA, Thornquist MD, Gaydos CA, Goodman GE, Vaughan TL. Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1624-1630.
60. Littman AJ, Jackson LA, Vaughan TL. Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 2005;14:773-778.
61. Koyi H, Branden E, Gnarpe J, Gnarpe H, Steen B. An association between chronic infection with Chlamydia pneumoniae and lung cancer: a prospective 2-year study. APMIS 2001;109:572-580.
62. Laurila AL, Anttila T, Laara E, Bloigu A, Virtamo J, Albanes D, Leinonen M, Saikku P. Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer. Int J Cancer 1997;74:31-34.
63. Kocazeybek B. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study. J Med Microbiol 2003;52:721-726.
64. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-2418.
65. Malkinson AM. Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res 2005;31:57-82.
66. Pages V, Fuchs RP. How DNA lesions are turned into mutations within cells? Oncogene 2002;21:8957-8966.
67. Sadowska AM, van Overveld FJ, Gorecka D, Zdral A, Filewska M, Demkow UA, Luyten C, Saenen E, Zielinski J, De Backer WA. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med 2005;99:241-249.
68. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-765.
69. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-743.
70. Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004;10:4266s-4269s.
71. Lam S, leRiche JC, McWilliams A, Macaulay C, Dyachkova Y, Szabo E, Mayo J, Schellenberg R, Coldman A, Hawk E, et al. A randomized phase IIb trial of Pulmicort Turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004;10:6502-6511.
72. Droms KA, Fernandez CA, Thaete LG, Malkinson AM. Effects of adrenalectomy and corticosterone administration on mouse lung tumor susceptibility and histogenesis. J Natl Cancer Inst 1988;80:365-369.
73. Estensen RD, Jordan MM, Wiedmann TS, Galbraith AR, Steele VE, Wattenberg LW. Effect of chemopreventive agents on separate stages of progression of benzo[alpha]pyrene induced lung tumors in A/Jmice. Carcinogenesis 2004;25:197-201.
74. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997;57:5489-5492.
75. Brown DW, Young KE, Anda RF, Felitti VJ, Giles WH. Re: asthma and the risk of lung cancer: findings from the Adverse Childhood Experiences (ACE). Cancer Causes Control 2006;17:349-350.
76. Brown DW, Young KE, Anda RF, Giles WH. Asthma and risk of death from lung cancer: NHANES II mortality study. J Asthma 2005;42:597-600.
77. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-116.
78. Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995;14:2627-2643.